This article explains, in educational terms, sirolimus-eluting stent — how the technology works and where it fits. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow.
Sirolimus-Eluting Stent Platform
Sirolimus is a widely used antiproliferative agent that interrupts the cell-cycle signaling responsible for excessive tissue growth inside a stent. Delivering sirolimus locally from the stent surface concentrates the drug at the treated segment while limiting systemic exposure. INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. The cobalt-chromium alloy underneath is intended to allow thin struts while preserving radial support, as described in the product documentation.
Design and Technical Notes
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Key Considerations
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
Frequently Asked Questions
What is the INVAMED drug-eluting stent called?
INVAMED's drug-eluting coronary stent is the ATLAS Drug Eluting Coronary Stent System, built on a cobalt-chromium L605 platform with a sirolimus coating.
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
The cobalt-chromium alloy underneath is intended to allow thin struts while preserving radial support, as described in the product documentation. Because a drug-coated balloon leaves nothing behind, it is one option a clinician may weigh when a metallic implant is less desirable. INVAMED's ATLAS Drug Eluting Coronary Stent System uses a cobalt-chromium L605 platform with 60 micrometer struts and a sirolimus coating dosed at 1 microgram per square millimeter with sustained controlled release. When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting. INVAMED's coronary portfolio includes guiding catheters, extension catheters, and microcatheters intended to support crossing and delivery in demanding anatomy. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU. Wire selection is a hands-on decision made by the operator according to lesion morphology and crossing strategy.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Inwire PTCA Guidewire: What Clinicians and Buyers Should Know
- Drug-eluting stent or Bare-metal stent? A Technical Comparison
- How long does a heart stent last?
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.